-
YM-358 potassium hydrate
- names:
potassium 5-(4'-((2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-2-ide hydrate
- CAS号:
161800-08-4
MDL Number: - MF(分子式): C22H23KN8O MW(分子量): 454.5793
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | potassium 5-(4'-((2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-2-ide hydrate |
| 英文别名 | YM-358 potassium hydrate; YM-358; YM 358; YM358. |
| CAS号 | 161800-08-4 |
| Inchi | InChI=1S/C22H21N8.K.H2O/c1-3-16-14-29(30-22(16)23-20(4-2)26-30)13-15-9-11-17(12-10-15)18-7-5-6-8-19(18)21-24-27-28-25-21;;/h5-12,14H,3-4,13H2,1-2H3;;1H2/q-1;+1; |
| InchiKey | OVKAVHGXKQGOMJ-UHFFFAOYSA-N |
| 分子式 Formula | C22H23KN8O |
| 分子量 Molecular Weight | 454.5793 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | YM-358 potassium hydrate(CAS:161800-08-4 ):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | YM-358 potassium hydrate is a angiotensin type 1 receptor antagonist potentially for the treatment of hypertension and chronic heart. YM358 is both orally active and long-lasting. YM358 has higher efficacy than enalapril for the treatment of hypertension. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Oka-Akagi T, Fujimori A, Shibasaki M, Matsuda-Satoh Y, Inagaki O, Yanagisawa I. Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in rats. Biol Pharm Bull. 2002 Jul;25(7):857-60. PubMed PMID: 12132657. |
| [2]Tokioka-Akagi T, Fujimori A, Shibasaki M, Inagaki O, Yanagisawa I. Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload. Jpn J Pharmacol. 2001 May;86(1):79-85. PubMed PMID: 11430476. |
| [3] Tokioka T, Shibasaki M, Fujimori A, Matsuda-Satoh Y, Uchida W, Inagaki O, Yanagisawa I. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81. PubMed PMID: 10706380. |
| [4] Sekine T, Kusano H, Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Developmental conversion of inotropism by endothelin I and angiotensin II from positive to negative in mice. Eur J Pharmacol. 1999 Jun 25;374(3):411-5. PubMed PMID: 10422785. |
| [5] Okazaki T, Suga A, Watanabe T, Kikuchi K, Kurihara H, Shibasaki M, Fujimori A, Inagaki O, Yanagisawa U. Studies on nonpeptide angiotensin II receptor antagonists. I. Synthesis and biological evaluation of pyrazolo[1,5-b][1,2,4]triazole derivatives with alkyl substituents. Chem Pharm Bull (Tokyo). 1998 Jan;46(1):69-78. PubMed PMID: 9468638. |
6: Shibasaki M, Fujimori A, Kusayama T, Tokioka T, Satoh Y, Okazaki T, Uchida W, Inagaki O, Yanagisawa I. Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs. Eur J Pharmacol. 1997 Sep 24;335(2-3):175-84. PubMed PMID: 9369371.7: Shibasaki M, Fujimori A, Takanashi M, Kusayama T, Tokioka T, Satoh Y, Okazaki T, Uchida W, Inagaki O, Yanagisawa I. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist. Eur J Pharmacol. 1997 Sep 24;335(2-3):167-73. PubMed PMID: 9369370.8: Yamaguchi N, Fujimoto K, Fujii T, Suzuki T, Kawashima K. Antihypertensive effect of repeatedly administered YM358, an angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol. 1997 Jan;73(1):83-91. PubMed PMID: 9032137.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


